Casgevy (exagamglogene autotemcel) Medical Drug Criteria
Customize your policy alerts
Sign up for all blue cross blue shield - kansas policy alerts
Know when blue cross blue shield - kansas releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior authorization, eligibility, and coverage conditions for a single-dose autologous gene therapy (Casgevy) for patients with sickle cell disease or transfusion-dependent beta thalassemia under BCBSKS.
Length of authorization changed from 'may not' to 'will not' be renewed; coverage limited to one treatment course (one dose).
Requirement that patient has not had a prior HSCT and for patients under 18, no known suitable 10/10 HLA matched related donor willing to participate in allogeneic HSCT.
Sickle cell disease criteria updated to require uncontrolled disease despite hydroxyurea OR crizanlizumab (or intolerance) or need for repeat transfusions; VOC threshold changed to two or more events in the previous year.
HCPCS code J3392 (exagamglogene autotemcel) added effective 01/01/2025 and J3590 removed.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.